Dr. Kent W. Small, MD
Ophthalmology (Ophthalmology Physician)
411 N Central Ave Ste 115
Glendale, CA 91203
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,166
Licensed in California since 1994, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: Tulane University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A53173 (first issued 1994; current) -
Retina Specialist (Ophthalmology) Physician
CA license A53173 (first issued 1994; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Carson Mcbeath and Boswell Inc (8 clinicians)
- Kent W Small MD A Medical Corporation (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,166
- Services billed
- 86,626
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 56,580 | 128 |
| Established patient complete exam of visual system | 3,758 | 1,067 |
| Injection of drug into eye | 2,407 | 339 |
| Imaging of retina | 2,294 | 638 |
| Photography of the retina | 1,833 | 1,074 |
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 1,495 | 58 |
| Injection, ranibizumab, 0.1 mg | 1,114 | 69 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 708 | 551 |
| Compounded drug, not otherwise classified | 662 | 158 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 495 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Cyclosporine Other prescribers in Glendale, CA | 251 |
| Brimonidine Tartrate Other prescribers in Glendale, CA | 241 |
| Restasis (cyclosporine) Other prescribers in Glendale, CA | 225 |
| Xiidra (lifitegrast) Other prescribers in Glendale, CA | 210 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Glendale, CA | 167 |
| Lumigan (bimatoprost) Other prescribers in Glendale, CA | 159 |
| Timolol Maleate Other prescribers in Glendale, CA | 151 |
| Cequa (cyclosporine) Other prescribers in Glendale, CA | 151 |
| Dorzolamide Hcl Other prescribers in Glendale, CA | 141 |
| Latanoprost Other prescribers in Glendale, CA | 114 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 125 payments worth $4,418 in total to this clinician.
| Astellas Pharma US Inc | $878 |
|---|---|
| Bausch & Lomb Americas Inc. | $481 |
| Sun Pharmaceutical Industries Inc. | $470 |
| Tarsus Pharmaceuticals, Inc. | $383 |
| Apellis Pharmaceuticals, Inc. | $370 |
| Samsara Vision | $307 |
| Alcon Vision LLC | $285 |
| Regeneron Healthcare Solutions, Inc. | $245 |
| Food and Beverage | $4,264 |
|---|---|
| Entertainment | $154 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Optos, Inc. Apr 11, 2025 | Entertainment NFC-700; PANORAMIC OPHTHALMOSCOPE; OCT OPHTHALMOSCOPE · OPHTHALMOLOGY · in-kind | $134 |
| Optos, Inc. Jun 26, 2025 | Entertainment NFC-700; PANORAMIC OPHTHALMOSCOPE; OCT OPHTHALMOSCOPE · OPHTHALMOLOGY · in-kind | $19.93 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $21,840 in research payments for these studies, mostly to the institutions running them.
- NRICH
Notal Vision, Inc. - Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Ani Pharmaceuticals, Inc. · Status unknown · NCT05322070
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.